Alessandro Sticchi

At 10 years, the second-generation SAPIEN XT was associated with lower survival and higher reintervention than surgery in the randomised PARTNER 2A trial, whereas the third-generation SAPIEN 3 matched surgery in a propensity-matched registry comparison. Two analyses, one lesson: long-term outcome is defined by the valve...

This session delves into the adoption of artificial intelligence in the cath lab, focusing on clinically useful risk prediction models for coronary and structural interventions. It covers advanced AI-guided intravascular imaging, machine learning applications for adverse event prediction, and critical evaluation of model validation and clinical...

This session reviews contemporary clinical outcomes of tricuspid valve interventions. Topics include interim results from the Cardiovalve replacement system trial, the impact of atrial fibrillation on tricuspid TEER, residual regurgitation implications, afterload mismatch post-intervention, and long-term bioprosthetic valve durability.

The study aimed to evaluate the impact of LAAC device implantation depth on local flow characteristics and its association with device-related thrombus using patient-specific computational fluid dynamics.

Alex Sticchi interviews Erwan Donal on the 2-year outcomes of the TRI-FR randomised trial evaluating transcatheter tricuspid edge-to-edge repair (T-TEER) versus medical therapy alone, as presented at ACC.26 in New Orleans.

The 6-year results of the Evolut Low Risk trial confirm the absence of significant differences in the composite primary endpoint between TAVR and surgery, but introduce an important nuance: the first signal of increased valve reintervention in the TAVR arm within this trial.

Alex Sticchi interviews Adam B. Greenbaum on the PROTECT head-to-head trial, comparing the new full-body Emboliner device with the first-generation Sentinel during TAVR, as presented at ACC.26 in New Orleans.

Live updates on a selection of major Late Breaking Clinical Trials of interest in interventional cardiology presented at the American College of Cardiology 2026 Scientific Sessions #ACC26

Transcatheter interventions have rapidly reshaped the management of tricuspid valve disease, with landmark trials establishing feasibility and early clinical benefit.

Beyond these pivotal studies, a series of less visible but highly informative papers addressed mechanisms, complications, patient phenotypes, and unintended consequences of intervention.

This curated selection highlights ten impactful tricuspid...

The present analysis compared major adverse cardiac events in patients with significant coronary stenosis (FFR ≤ 0.80 or visual stenosis ≥ 90 %) versus those with non-significant stenosis (FFR > 0.80).

This session presents pivotal advances in valvular and structural heart interventions, covering the SMART-MV trial on mitral valvotomy safety, outcomes of TAVR patients with tricuspid regurgitation undergoing TEER, and the application of the FLOWer embolic protection system across structural heart procedures. Additionally, it explores the impact...

This session presents a series of challenging and unusual TAVI cases, addressing complex scenarios such as persistent gradients after valve-in-valve procedures, advanced sealing techniques for nodules, innovative snare methods, emergency TAVI following diagnostic catheterisation, combined aortic valve and aorta interventions, and the crucial role of echocardiography...

Alessandro Sticchi provides us with a curated overview of the late-breaking trials he found most relevant for interventional cardiologists from AHA 2025.

Alex Sticchi provides his take on the iCABG trial presented by Rasa Ordiene at TCT 2025, in San Francisco.

Alex Sticchi interviews Lei Song on the IRONMAN II trial he presented at TCT 2025, in San Francisco.

Thanks to the contribution of a team of interventional cardiologists from around the globe, get the international perspective on Late-breaking Clinical Trials and Science released at TCT 2025 - check out the list below.

In this interview, Alex Sticchi speaks with Fabien Praz and Michael Borger, co-chairs of the 2025 ESC/EACTS Valvular Guidelines Task Force. They discuss the major updates, including the central role of multimodality imaging, the lowered age threshold for TAVI, the distinction between atrial and ventricular secondary...

Alex Sticchi provides his take on the new ESC Valvular Guidelines presented at the ESC Congress 2025 in Madrid.

Alex Sticchi provides his take on the results of the OPINION trial presented by Yang Wang at the ESC Congress 2025 in Madrid.

Stay updated with the latest in interventional cardiology at #ESCCongress 2025!

Explore the latest innovations in transcatheter aortic valve implantation (TAVI) devices with a focus on coronary protection strategies, cerebral embolic protection integration, management of ventricular migration, and overcoming anatomical challenges such as bicuspid and rheumatic valve disease using novel platforms.

Explore the multifaceted challenges in patients undergoing mitral TEER when additional mitral and tricuspid pathologies coexist. This session reviews data from the EXPANDed studies on tricuspid regurgitation post-mitral TEER, one-year outcomes based on cardiac damage extent, pulmonary hypertension dynamics, and the long-term mortality causes in this...

The objective of this study was to validate standardised clinical criteria for BVD and evaluate its association with mortality and rehospitalisation, thereby guiding optimal valve selection in clinical practice.

Alex Sticchi interviews Saibal Kar about the two-year results of the Triluminate pivotal trial, unveiled at ACC.25 in Chicago.

After revisiting the one-year findings and outlining the study design, Saibal Kar highlights key takeaways: at two years, TriClip therapy significantly reduced heart failure hospitalisations compared to medical...

This study demonstrates that OCT-defined TCFA is a superior prognostic marker compared to μQFR for assessing NCLs in AMI patients.

Live updates on a selection of major Late Breaking Clinical Trials of interest in interventional cardiology presented at the American College of Cardiology 2025 Scientific Sessions #ACC25

Immerse yourself in a captivating collection of featured cases showcasing the latest advances in transcatheter tricuspid valve interventions. Witness groundbreaking techniques, including the first TTVR designed to reduce afterload mismatch, the management of atrial embolization, and the use of intracardiac echocardiography. Explore complex anatomies, failed prior...

Alessandro Sticchi provides his take on the OPTION Trial presented at AHA 2024 in Chicago.

Stay up to date with what is new and hot in interventional cardiology at #AHA24 in Chicago.

Alex Sticchi provides his take on the results of the TRISCEND II trial presented by Susheel K. Kodali and Suzanne V. Arnold at TCT 2024 in Washington.

Also watch the interview with Susheel K. Kodali